

REMARKS

The Office Action has withdrawn the restriction requirement of November 30, 2006 and has placed a new restriction requirement.

Claims 81-87 and 90-97 are currently pending in this application. Applicants elect, with traverse, the claims of Group I (claims 81-84, 90, and 94) for further prosecution. The available evidence does not justify the restriction requirement. There is a likelihood that the search results would overlap to some extent. Further, the United States Patent and Trademark Office often grants a single patent with the claims directed to compounds, compositions, and method of use.

The restriction requirement is between product and process claims. Applicants have elected product claims. The process claims are dependent upon product claims and include all of the limitations of the product claims. In the event the Office maintains the restriction requirement, applicants respectfully request the Office to rejoin the process claims when the product claims are found allowable.

A favorable decision is solicited. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of this application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Xavier Pillai, Ph.D., Reg. No. 39,799
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6731
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: January 29, 2007

M:\clients\NIH\Amd\231461 ROA (1-29-07).doc